High-risk neuroblastoma stem cell treatment after initial response
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were younger than 30 when you were diagnosed with neuroblastoma.
- After initial chemotherapy, your scans/bone marrow (disease evaluation) showed complete or partial response, or stable disease.
- Your blood counts have recovered enough after the last chemotherapy phase to safely proceed to the next treatment.
- You do not have an infection that is not under control right now.
- You must be able to provide enough frozen stem cells from before the consolidation starts (with backup cells strongly encouraged).
- Your heart, lungs, liver, and kidneys must meet minimum function checks, and you must have recovered from the side effects of the last chemotherapy cycle.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a stem cell transplant from a donor can help children with high-risk neuroblastoma. It aims to replace damaged bone marrow with healthy cells to fight the cancer.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This trial tests a new treatment combining your child's own immune cells (NK cells) with an antibody that targets neuroblastoma cells. It is for children who have just finished standard treatment or whose cancer has come back or not responded, and aims to improve outcomes.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.